SCHEMBL21748908

SCHEMBL21748908

O=C1CCN(Cc2ccccc2)C2(CC2)C1

nearest known ligand 0.44

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
DDB1 Q16531 1/20 0.44
CRBN Q96SW2 1/20 0.44
SIGMAR1 Q99720 6/20 0.43
KMT2A Q03164 2/20 0.43
MEN1 O00255 1/20 0.43
GAA P10253 2/20 0.41
L3MBTL1 Q9Y468 1/20 0.41
EPHX2 P34913 2/20 0.40
DRD2 P14416 2/20 0.40
HTR2A P28223 2/20 0.40
HTR2C P28335 2/20 0.40
HTR2B P41595 2/20 0.40
CYP3A4 P08684 1/20 0.39
HSD17B10 Q99714 1/20 0.39
F2 P00734 1/20 0.39
PLG P00747 1/20 0.39
ELANE P08246 1/20 0.39
CTSG P08311 1/20 0.39
CMA1 P23946 1/20 0.39
CTRC Q99895 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL27229930 0.94 KMT2A (0.44) DDB1CRBNSIGMAR1KMT2AMEN1
SCHEMBL29584384 0.86 DDB1 (0.41) DDB1CRBNSIGMAR1KMT2AMEN1
SCHEMBL4036910 0.82 DDB1 (0.45) DDB1CRBNSIGMAR1KMT2AMEN1
SCHEMBL3061605 0.81 GAA (0.45) DDB1CRBNSIGMAR1KMT2AMEN1
SCHEMBL1557924 0.76 KMT2A (0.49) DDB1CRBNSIGMAR1KMT2AMEN1
SCHEMBL22394900 0.71 KMT2A (0.44) SIGMAR1KMT2AMEN1L3MBTL1EPHX2
SCHEMBL30594794 0.70 SIGMAR1 (0.57) SIGMAR1KMT2AMEN1CYP3A4HSD17B10
SCHEMBL4726 0.70 SIGMAR1 (0.68) DDB1CRBNSIGMAR1KMT2AMEN1
SCHEMBL30924710 0.69 SIGMAR1 (0.45) SIGMAR1KMT2AMEN1L3MBTL1EPHX2
SCHEMBL25081010 0.69 ALDH1A1 (0.43) SIGMAR1CYP3A4HSD17B10

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20250049772-A1 PIPERIDINYL-3-(ARYLOXY)PROPANAMIDES AND PROPANOATES TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2025-02-13 US disclosed
US-12005054-B2 Piperidinyl-3-(aryloxy)propanamides and propanoates TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2024-06-11 US disclosed
US-20230021834-A1 PIPERIDINYL-3-(ARYLOXY)PROPANAMIDES AND PROPANOATES TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2023-01-26 US disclosed
US-11045457-B2 Piperidinyl-3-(aryloxy)propanamides and propanoates TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2021-06-29 US disclosed
EP-3759094-A1 PIPERIDINYL-3-(ARYLOXY)PROPANAMIDES AND PROPANOATES Takeda Pharmaceutical Company Limited (JP) 2021-01-06 EP disclosed
US-20200061041-A1 PIPERIDINYL-3-(ARYLOXY)PROPANAMIDES AND PROPANOATES TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2020-02-27 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11045457-B2 Piperidinyl-3-(aryloxy)propanamides and propanoates SSTR4, SSTR3, NPY4R DDB1 4838/4885CRBN 3091/4885SIGMAR1 180/4885
US-12005054-B2 Piperidinyl-3-(aryloxy)propanamides and propanoates SSTR4, SSTR3, NPY4R DDB1 4838/4885CRBN 3091/4885SIGMAR1 180/4885
US-20250049772-A1 PIPERIDINYL-3-(ARYLOXY)PROPANAMIDES AND PROPANOATES SSTR4, SSTR3, NPY4R DDB1 4838/4885CRBN 3091/4885SIGMAR1 180/4885
US-20200061041-A1 PIPERIDINYL-3-(ARYLOXY)PROPANAMIDES AND PROPANOATES SSTR4, SSTR3, NPY4R DDB1 4838/4885CRBN 3091/4885SIGMAR1 180/4885
US-20230021834-A1 PIPERIDINYL-3-(ARYLOXY)PROPANAMIDES AND PROPANOATES SSTR4, SSTR3, NPY4R DDB1 4838/4885CRBN 3091/4885SIGMAR1 180/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.